Skip To Main Content
Jonathan Gardner on Muck Rack

Jonathan Gardner

New York
As seen in: LinkedIn, Yahoo Life, Yahoo Finance, Business Wire, Stuff.co.nz, The Conversation, The Star (Malaysia), Yahoo, Digiday, Radio New Zealand (RNZ) and
Your favorite rapper's favorite wrapper. Marketing and comms. Working at the intersection of tech and content.

Get in touch with Jonathan

Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

AstraZeneca scores in lung cancer; Sandoz inks a China deal Original

|
By Jonathan Gardner
| BioPharma Dive Verified
Today, a brief rundown of news involving AstraZeneca and a legal battle between Celgene shareholders and Bristol Myers Squibb, as well as updates from MapLight Therapeutics and Sandoz that you may have missed. A combination of AstraZeneca’s drug Tagrisso and Hutchmed’s Orpathys helped people with a type of mutated lung cancer live longer than those given chemotherapy, the companies said Monday.
Open in Who Shared View Duplicates (3) Issue with article?

Ex-Legend CEO takes helm at biotech startup scouring the globe for drugs

|
By Jonathan Gardner
| Yahoo Finance Verified
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The CEO who helped guide development of the top-selling cell therapy for multiple myeloma will take the reins of a young startup searching the world for new drug prospects. On Tuesday, that startup, K2 Therapeutics, announced that former Legend Biotech CEO Ying Huang has been named its new leader.
Open in Who Shared Issue with article?

AstraZeneca, GSK intensify China ties with Sino Biopharm deals Original

|
By Jonathan Gardner
| BioPharma Dive Verified
Dive Brief: China-based drugmaker Sino Biopharm said Wednesday it signed new deals with the U.K.’s two biggest pharma companies. Through one collaboration, AstraZeneca is licensing rights to a drug Sino is developing for lung diseases. In the other, Sino is gaining ownership in China of GSK’s marketed respiratory medicines Trelegy and Anoro.
Open in Who Shared View Duplicates (3) Issue with article?
See all 203 licensed articles (205 Total)